Catalyst Event
Exelixis Inc (EXEL) · Other
From KEDI Global Longevity Bio Index (KGLB)
5/30/2026, 12:00:00 AM
Announced results from a subgroup analysis of the Phase 3 CABINET pivotal trial at ASCO 2026, showing CABOMETYX® (cabozantinib) significantly improved progression-free survival in patients with advanced neuroendocrine tumors (NET).
Korean Translation
ASCO 2026에서 3상 CABINET 주요 임상시험의 하위 그룹 분석 결과를 발표했으며, CABOMETYX®(카보잔티닙)가 진행성 신경내분비종양(NET) 환자의 무진행 생존기간을 유의미하게 개선했음을 보임.
Related Recent Events
Exelixis Inc (EXEL) · Other
U.S. FDA PDUFA target action date for zanzalintinib (December 3, 2026) is a potential first approval for a major new franchise; >10% price impact is estimated, scheduled.
12/3/2026, 12:00:00 AM
Bristol-Myers Squibb Co (BMY) · Other
The U.S. FDA set a PDUFA target action date for iberdomide on 2026-08-17; importance is Low as the setting of a PDUFA date is a procedural event with minor price impact.
8/17/2026, 12:00:00 AM
Moderna Inc (MRNA) · Other
FDA Prescription Drug User Fee Act (PDUFA) target action date for its seasonal flu vaccine (mRNA-1010) on August 5, 2026; Medium importance as PDUFA dates are major catalysts for biotech stocks, scheduled.
8/5/2026, 12:00:00 AM
Pfizer Inc (PFE) · Earnings Release
Next quarterly earnings for Q2 2026 are expected to be announced on August 4, 2026; medium impact estimated based on historical volatility during earnings releases, expected.
8/4/2026, 12:00:00 AM
Sanofi (SNY) · Earnings Release
Sanofi's Q2 2026 earnings results release on July 30, 2026, is expected to have a Medium impact as earnings typically drive 5-10% price volatility scheduled.
7/30/2026, 12:00:00 AM
AbbVie Inc (ABBV) · Earnings Release
Q2 2026 earnings release for 2026-07-30. Low importance as it is a routine announcement scheduled.
7/30/2026, 12:00:00 AM